---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-017264"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2025-01-30T23:59:59+00:00"
generated_at: "2026-05-27T05:32:10.269833+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Verrica receives Nasdaq deficiency notice; stock below $1 for 30 days, 180-day cure period until July 23, 2025

## Summary
- Nasdaq notified Verrica on Jan 24, 2025 that bid price closed below $1.00 for 30 consecutive days, violating Listing Rule 5450(a)(1).
- Company has 180 days (until July 23, 2025) to regain compliance by closing at $1.00+ for 10 consecutive business days.
- If not cured, Verrica may transfer to Nasdaq Capital Market by paying $5,000 fee and meeting other standards except bid price.
- Company is considering options including reverse stock split and application to transfer to Nasdaq Capital Market.
- No immediate impact on listing; delisting risk if compliance not achieved within cure periods.

## SEC filing metadata
- accession: 0001193125-25-017264
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2025-01-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312525017264/0001193125-25-017264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312525017264/d913894d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-017264
- JSON: https://secwatch.observer/filing/0001193125-25-017264.json
- Plain text: https://secwatch.observer/filing/0001193125-25-017264.txt

## Source-grounded claims
- claim_id: 2f47edf8bdf629d852d22d660ab5a361e55362a3
  claim: Verrica Pharmaceuticals Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  evidence_excerpt: January 24, 2025, Verrica Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312525017264/0001193125-25-017264-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.